The Journal of Phytopharmacology, 2020;9(6):403-409 DOI:10.31254/phyto.2020.9604

Research Article

Acute and subacute toxicity profiles on Siddha drug Thulasi Ennai in wistar rats

S. Sonitha¹ , D. Sivaraman² , V. Rani³

S. Sonitha,D. Sivaraman,V. Rani

1. PG Research Scholar, Kuzhandhai Maruthuvam Department, Government Siddha Medical College, Chennai, 600106, Tamil Nadu, India
2. Scientist, Centre for Laboratory Animal Technology and Research, Sathyabama Institute of Science and Technology, Chennai, 600119, Tamil Nadu, India
3. HOD of Kuzhandhai Maruthuvam Department, Government Siddha Medical College, Chennai 600106, Tamil Nadu, India

*Author to whom correspondence should be addressed.

Received: 1st September, 2020 / Accepted: 11th October, 2020

Abstract

Medicinal plants have been used in traditional medicines for their unmatched availability of bioactive compounds. Asthma is the most common chronic disease among children worldwide. It is ranked 16th among the leading causes of years lived with disability. Medicinal plants have placed a vital role in the siddha system of medicine over centuries to cure acute and chronic illness. The aim of the present study was to investigate toxicity analysis to evaluate safety of the siddha drug Thulasi Ennai in vivo in wistar albino rats. Thulasi Ennai is a polyherbal siddha formulation mentioned in the ancient siddha books and literature, indicated to cure childhood bronchial asthma. In this study, Thulasi Ennai administered orally at a single dose of 2000mg/kg body weight and monitored for 14 days. For subacute toxicity study, Thulasi Ennai was orally administered in different doses of 200,400mg/kg body weight, daily for 28 days. At the end of each study physical parameters, hematological, biochemical and histopathological analysis were evaluated. No animals in each group of acute or subacute toxicity study showed mortality or clinical signs of toxicity throughout the study. Hence, the results of the study indicate a safe toxicological profile of Thulasi Ennai.